CSU Animal Cancer Center Clinical Trial
Reversal of Tumor Immune Suppression with Losartan and Toceranib for Treatment of Osteosarcoma Metastases
Purpose of the study:
- Toceranib and losartan have been shown to inhibit certain immune cells to allow the immune system to better recognize cancer
- This study assesses this combination of medications used specifically in patients with osteosarcoma.
Primary Eligibility Criteria:
- Dogs with confirmed osteosarcoma
- Have undergone surgical resection of the primary tumor, and have lung metastases visible on chest x-rays.
- Systemically healthy otherwise.
- Initial diagnostic testing to ensure eligibility for study
- Oral losartan given at home twice daily alone for first 2 weeks, then oral toceranib added which is administered at home every other day.
- Rechecks at 1, 2, 4, and 8 weeks, and then every 4 weeks after that; dog must stay at hospital for full day at 2 week visit for blood sample collections for study purposes.
- Follow appointment schedule required by study protocol
- Be comfortable administering oral medications
- Toceranib and losartan will be provided at no cost
- Chest x-rays done every 8 weeks will be paid for by study